Otsuka : Announces Change in Status of Representative Director (125KB)
March 27, 2015 at 02:32 am EDT
Share
M a r c h 27 , 20 1 5
Otsuka Holdings Announces Change in Status of Representative Director
Tokyo, Japan, March 27, 2015 ―Otsuka Holdings Co., Ltd., (Head office: Chiyoda-ku, Tokyo, Japan; President and Representative Director, CEO: Tatsuo Higuchi) today announced a change in status of a representative director as detailed below. The change was ratified today at the annual general shareholders' meeting and a meeting of its Board of Directors. The resolution was determined at the meeting of its Board of Directors on February 13, 2015.
Particulars
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity:
- manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices;
- manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements;
- production of mineral waters, beverages and foods (2.1%);
- other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc.
Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%).
Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),